Bibliography
- Thurn KT, Thomas S, Moore A, et al. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2011;7:263-83
- Balasubramanian S, Verner E, Buggy JJ. Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett 2009;280:211-21
- Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012;119:2579-89
- Balasubramanian S, Ramos J, Luo W, et al. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 2008;22:1026-34
- Minami J, Suzuki R, Mazitschek R, et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia 2013, doi:10.1038/leu.2013.231
- Bantscheff M, Hopf C, Savitski MM, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011;29:255-65
- Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 2012;4:505-24
- Morphy R, Rankovic Z. Designing multiple ligands – medicinal chemistry strategies and challenges. Curr Pharm Des 2009;15:587-600
- Zhang X, Zhang J, Tong L, et al. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents. Bioorg Med Chem 2013;21:3240-4
- Fischer J, Wang TT, Kaldre D, et al. Synthetically accessible non-secosteroidal hybrid molecules combining vitamin D receptor agonism and histone deacetylase inhibition. Chem Biol 2012;19:963-71
- Zhang X, Su M, Chen Y, et al. The design and synthesis of a new class of RTK/HDAC dual-targeted inhibitors. Molecules 2013;18:6491-503
- Lai CJ, Bao R, Tao X, et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res 2010;70:3647-56
- Guerrant W, Patil V, Canzoneri JC, et al. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. J Med Chem 2012;55:1465-77
- Guerrant W, Patil V, Canzoneri JC, et al. Dual-acting histone deacetylase-topoisomerase I inhibitors. Bioorg Med Chem Lett 2013;23:3283-7
- Griffith D, Morgan M, Marmion CJ. A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity. Chem Commun 2009;6735-7
- Brabec V, Griffith DM, Kisova A, et al. Valuable insight into the anticancer activity of the platinum-histone deacetylase inhibitor conjugate, cis-[Pt(NH(3))(2)malSAHA(-2H))]. Mol Pharm 2012;9:1990-9
- Yang J, Sun X, Mao W, et al. Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy. Mol Pharm 2012;10:2793-800
- Chen L, Wilson D, Jayaram HN, et al. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. J Med Chem 2007;50:6685-91
- Chetan B, Bunha M, Jagrat M, et al. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity. Bioorg Med Chem Lett 2010;20:3906-10
- Chen JB, Chern TR, Wei TT, et al. Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment. J Med Chem 2013;56:3645-55
- Passarella D, Comi D, Vanossi A, et al. Histone deacetylase and microtubules as targets for the synthesis of releasable conjugate compounds. Bioorg Med Chem Lett 2009;19:6358-63